ImetelChat

From kmall YMB: @Jerry Reading through a company's proxy one must consider "legalities"......this has been obviously scrutinized over by Gerons team of lawyers - which there are about a half dozen or so. From what I was able to skim through and what Hunter has aptly pointed out, I for one feel quite...

Hat tip to hunt YMB for doing the Digging “ . If approved for marketing by regulatory authorities, we plan to commercialize imetelstat in the United States and seek potential commercialization partners for territories outside of the United States. We hold issued patents covering imetelstat compositi...

More later.

Me too, brother. As the Ram Bam said, if not now, when?

GREAT post earfool, thank you. This may explain the findings presented in the Hu poster at last year's ASH. bp

Note also from last ASH: https://www.geron.com/file.cfm/53/docs/ ... 9_Wang.pdf

https://www.sciencedirect.com/science/a ... 1X20307798

May turn up at EHA. No doubt Incyte taking careful note. Regards, bp

Correction: EHA Abstract release May 14th.

Hello fellow board members, hope everyone is safe. Here is what we have to look forward to in the next few weeks: 1. Release of EHA abstracts, should be in first week of May 2. Results of FDA meeting, should be around mid May 3. Annual shareholders meeting June 5th 4. EHA virtual meetings second wee...

Yes, Bill is an acquired taste. I have always felt he had much to contribute and I hope to see him eating some serious crow (not CRO ) soon if we see favorable action by the FDA. Bill despite his detractors is the only person I know who has worked directly with Imetelstat and contributed to the body...

Hi Hunt, thank you for your contributions (as always) to this board. I generally agree with your assessment and feel the potential for Geron has been long underestimated and that were coming into exciting times. While I have agreed with your black swan theory in general, I am concerned that the actu...

If you are looking for the new shareholders letter, it is in plain sight on the Geron website. I missed it at first since there is nothing to identify it as new and it fades into the background of the design of the site. Basically the web site is insipid with that ridiculous rocking horse. Time for ...

Blood tax services listed here at about 3600. https://www.hopkinsmedicine.org/the_johns_hopkins_hospital/_docs/jhh_charges.pdf I have seen other estimates closer to 7 to 8 hundred per unit. Cost has to consider collection, screening for blood borne disease (including it appears COVID19), preparation...

If there are 40,000 MDS cases in the US and Imet can be applied to 85% of them per Geron's slides, and if each patients Tx requirements goes down by 2 units every 2 months (12 units/year--this is very conservative but allows for not all MDS patients having a tx requirement), then 408,000 units of bl...

STA, anemia amelioration is an issue not only for MDS but also AML and MF (a secondary endpoint in the MF study). Your point is relevant, important and right on. The FDA, with low risk to them and to patients could allow compassionate use in high TR, lower risk patients based on the current data. It...

STA, agree but there has to be blood available and blood from good donors which is getting scarcer.

Today's PR is hardly surprising and I have mentioned in previous posts on SA and maybe here too that major contributing sites like Italy, Israel, South Korea will be literally shut down regarding ongoing clinical studies. I think we need to take a worse case look and assume that no new patients are ...

Bill W (Chang ho) would be a good one to answer this but it would require him to take the question seriously and avoid a glib response. You question calls for an in depth scholarly response. I am asking Bill W our anyone equipped to answer, to rise to the challenge. bp

Ryan, my money is on AA. 3 groups providing RWD to bolster original Janssen study (7month), now with Moffit, Lake Success and Italian center should satisfy FDA if MOS in R/R patients in line with Moffit study. bp